GlobeNewsWire
21 Jun 2026, 21:00 UTC · 11w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
5 claims · each scored for market impact
The Phase 3 VELA-1 and VELA-2 trials showed SLK outperformed a competitor IL-17-A & F inhibitor by over 10% in HiSCR75, HiSCR100, and IHS4-100 response rates. — Direct evidence of superior efficacy against a competing drug strongly increases the likelihood of market leadership and a 'best-in-class' commercial profile.
+0.80Week 52 results for SLK in moderate-to-severe HS showed 67.2% of patients achieved HiSCR75 and 33.1% achieved HiSCR100. — Positive late-stage clinical data is the primary driver for biotech valuation and provides the basis for FDA approval.
+0.60Interim Week 24 data from the VELA-TEEN trial showed a ~68% HiSCR75 response rate in adolescent patients, exceeding rates seen in the adult program. — Successful expansion into the adolescent population increases the total addressable market and suggests a stronger effect in earlier-stage disease.
+0.50Continue reading
5 related stories
Search tags
Approximately 90% of patients rolled over into the two-year open-label extension (VELA-OLE), confirming the tolerability of the 120mg Q4W dosing regimen. — High retention and dosing convenience are critical for long-term patient adherence and competitive advantage in chronic disease treatment.
+0.40MoonLake Immunotherapeutics will host an Investor Day webcast on June 22, 2026, featuring an open Q&A session. — Investor days are routine events, though they can provide catalysts for further price discovery through management commentary.
+0.10Which stocks this story touches
The company reported positive Phase 3 clinical trial results showing leading efficacy and durable improvements for its HS therapy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
19h ago
